GB0307860D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0307860D0
GB0307860D0 GBGB0307860.7A GB0307860A GB0307860D0 GB 0307860 D0 GB0307860 D0 GB 0307860D0 GB 0307860 A GB0307860 A GB 0307860A GB 0307860 D0 GB0307860 D0 GB 0307860D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0307860.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0307860.7A priority Critical patent/GB0307860D0/en
Publication of GB0307860D0 publication Critical patent/GB0307860D0/en
Priority to MXPA05010707A priority patent/MXPA05010707A/es
Priority to BRPI0409170-1A priority patent/BRPI0409170A/pt
Priority to CNB2004800092188A priority patent/CN100546581C/zh
Priority to PCT/EP2004/003518 priority patent/WO2004087161A1/en
Priority to CA002521274A priority patent/CA2521274A1/en
Priority to US10/550,381 priority patent/US20060194766A1/en
Priority to JP2006504970A priority patent/JP2006522062A/ja
Priority to AU2004226825A priority patent/AU2004226825B2/en
Priority to EP04725366A priority patent/EP1620103A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
GBGB0307860.7A 2003-04-04 2003-04-04 Organic compounds Ceased GB0307860D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0307860.7A GB0307860D0 (en) 2003-04-04 2003-04-04 Organic compounds
EP04725366A EP1620103A1 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders
PCT/EP2004/003518 WO2004087161A1 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders
BRPI0409170-1A BRPI0409170A (pt) 2003-04-04 2004-04-02 combinações compreendendo drogas antiepilépticas para o tratamento de distúrbios neurológicos
CNB2004800092188A CN100546581C (zh) 2003-04-04 2004-04-02 用于治疗神经病学病症的包含抗癫痫药的组合
MXPA05010707A MXPA05010707A (es) 2003-04-04 2004-04-02 Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos.
CA002521274A CA2521274A1 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders
US10/550,381 US20060194766A1 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders
JP2006504970A JP2006522062A (ja) 2003-04-04 2004-04-02 神経学的障害の処置のための抗癲癇剤を含む組み合わせ
AU2004226825A AU2004226825B2 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0307860.7A GB0307860D0 (en) 2003-04-04 2003-04-04 Organic compounds

Publications (1)

Publication Number Publication Date
GB0307860D0 true GB0307860D0 (en) 2003-05-14

Family

ID=9956223

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0307860.7A Ceased GB0307860D0 (en) 2003-04-04 2003-04-04 Organic compounds

Country Status (10)

Country Link
US (1) US20060194766A1 (enExample)
EP (1) EP1620103A1 (enExample)
JP (1) JP2006522062A (enExample)
CN (1) CN100546581C (enExample)
AU (1) AU2004226825B2 (enExample)
BR (1) BRPI0409170A (enExample)
CA (1) CA2521274A1 (enExample)
GB (1) GB0307860D0 (enExample)
MX (1) MXPA05010707A (enExample)
WO (1) WO2004087161A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2164489A2 (en) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CN112789042A (zh) 2018-09-28 2021-05-11 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) * 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
GB1028234A (en) * 1964-01-06 1966-05-04 Ici Ltd New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
IT1261808B (it) * 1993-07-06 1996-06-03 Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi
WO1998017692A1 (en) * 1996-10-19 1998-04-30 University Of Wales, Bangor Preparation of chemically reactive polysaccharides
TR199900897T2 (xx) * 1996-10-24 1999-07-21 Novartis Ag Ornat�lm�� aminoalkanfosfonik asitler.
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
CN1265889A (zh) * 1999-03-06 2000-09-13 王学勇 一种治疗癫痫病的药物
IL149530A0 (en) * 1999-12-01 2002-11-10 Ucb Sa A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
KR20050044396A (ko) * 2001-11-12 2005-05-12 노파르티스 아게 정동 및 주의력 장애 및 신경병성 통증 치료용 의약제조에 사용하기 위한 모노히드록시카르바마제핀

Also Published As

Publication number Publication date
AU2004226825B2 (en) 2007-08-16
BRPI0409170A (pt) 2006-04-11
MXPA05010707A (es) 2005-12-12
WO2004087161A1 (en) 2004-10-14
CA2521274A1 (en) 2004-10-14
JP2006522062A (ja) 2006-09-28
AU2004226825A1 (en) 2004-10-14
EP1620103A1 (en) 2006-02-01
US20060194766A1 (en) 2006-08-31
CN100546581C (zh) 2009-10-07
CN1767832A (zh) 2006-05-03

Similar Documents

Publication Publication Date Title
GB0414440D0 (en) Organic compounds
IL175435A0 (en) Organic compounds
GB0301259D0 (en) Organic compounds
GB0303503D0 (en) Organic compounds
GB0306715D0 (en) Organic compounds
GB0319227D0 (en) Organic compounds
GB0302876D0 (en) Organic compounds
GB0307860D0 (en) Organic compounds
GB0300095D0 (en) Organic compounds
GB0302748D0 (en) Organic compounds
GB0301471D0 (en) Organic compounds
GB0301938D0 (en) Organic compounds
GB0311971D0 (en) Organic compounds
GB0303506D0 (en) Organic compounds
GB0307277D0 (en) Organic compounds
GB0307440D0 (en) Organic compounds
GB0306071D0 (en) Organic compounds
GB0306070D0 (en) Organic compounds
GB0302991D0 (en) Organic compounds
GB0302750D0 (en) Organic compounds
GB0300591D0 (en) Organic compounds
GB0303867D0 (en) Organic compounds
GB0304642D0 (en) Organic compounds
GB0302874D0 (en) Organic compounds
GB0303323D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)